Shalini Makawita

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 4

Top Topics

Prognostic Factors

Placebo Controlled

Top Venues

JCO precision oncology

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Shalini Makawita, Sunyoung Lee, Elisabeth Kong, Lawrence N Kwong, Zeyad Abouelfetouh, Anaemy Danner De Armas, Lianchun Xiao, Karthikeyan Murugesan, Natalie Danziger, Dean C Pavlick, Anil Korkut, Jeffery S Ross, Milind M Javle
Comprehensive Immunogenomic Profiling of IDH1- / 2 -Altered Cholangiocarcinoma. JCO precision oncology 8 (2024)
Shalini Makawita, Sunyoung Lee, Elisabeth Kong, Lawrence N Kwong, Zeyad Abouelfetouh, Anaemy Danner De Armas, Lianchun Xiao, Karthikeyan Murugesan, Natalie Danziger, Dean C Pavlick, Anil Korkut, Jeffery S Ross, Milind M Javle
Comprehensive Immunogenomic Profiling of IDH1- / 2 -Altered Cholangiocarcinoma. JCO precision oncology 8 (2024)
Shalini Makawita, Sunyoung Lee, Elisabeth Kong, Lawrence N Kwong, Zeyad Abouelfetouh, Anaemy Danner De Armas, Lianchun Xiao, Karthikeyan Murugesan, Natalie Danziger, Dean C Pavlick, Anil Korkut, Jeffery S Ross, Milind M Javle
Comprehensive Immunogenomic Profiling of IDH1- / 2 -Altered Cholangiocarcinoma. JCO precision oncology 8 (2024)
Shalini Makawita, Ghassan K Abou-Alfa, Sameek Roychowdhury, Saeed Sadeghi, Ivan Borbath, Lipika Goyal, Allen Cohn, Angela Lamarca, Do Youn Oh, Teresa Macarulla, Rachna T Shroff, Michael F Howland, Ai Li, Terry Cho, Amit Pande, Milind M Javle
Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial. Future oncology (London, England) 16 (30) (2020)